No Data
No Data
junshi bio (688180.SH): The new drug application for Angoriximab injection was approved.
JUNSHI BIO (688180.SH) announced on October 11th that the company learned from the website of the National Medical Products Administration that the NMPA approved the company's application for the commercialization of Angoriximab injection (recombinant humanized anti-PCSK9 monoclonal antibody injection, trade name: JUNSHIDA) for the treatment of primary hypercholesterolemia (non-familial) and diversified bond lipid abnormalities in adults. This is the company's fifth approved commercial product. Indications: In addition to dietary control, in combination with statins, or in combination with statins and ezetimibe, for use in moderate to moderate dose.
[Brokerage Focus] China Post Securities expects the pharmaceutical sector to continue to rise uniformly, suggesting prioritizing the layout of various segmented sectors and leading companies in the first and second tiers during the general rise phase.
Golden Herald Financial News | China Post Securities stated that since the end of September, the pharmaceutical sector has been boosted by the national comprehensive incremental policy, solidly promoting the economy towards a higher-quality structure under the heavy bullish push, leading to a rapid rebound of the index by about 29%, reversing the continuous decline of nearly 4 years. Looking at the current PE (TTM), A-share pharmaceuticals are at 32 times, and Hong Kong stocks at 23 times. The previous continuous decline has already deviated from the fundamentals. The bank believes that the increase in market risk appetite will accelerate the sector's valuation repair. As of H1 2024, the institutions hold a 7.3% stake in the CSI SWS Health Care Index sector, which, although slightly lower than the end of 2023, still remains at a historically high level, indicating a general positive sentiment among institutions.
Subdued Growth No Barrier To Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) With Shares Advancing 32%
JUNSHI BIO: 2024 Interim Report
Junshi Biosciences Gets Rights for IAMA-001 Nasal Spray in Greater China; Shares Soar 10%
Junshi Biosciences Gets Nod to Trial WJ47156 Tablets as Tumor Drug; Shares Soar 10%
No Data
No Data